MX2022014167A - Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. - Google Patents
Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada.Info
- Publication number
- MX2022014167A MX2022014167A MX2022014167A MX2022014167A MX2022014167A MX 2022014167 A MX2022014167 A MX 2022014167A MX 2022014167 A MX2022014167 A MX 2022014167A MX 2022014167 A MX2022014167 A MX 2022014167A MX 2022014167 A MX2022014167 A MX 2022014167A
- Authority
- MX
- Mexico
- Prior art keywords
- spike protein
- rna replicon
- corona virus
- virus spike
- replicon encoding
- Prior art date
Links
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen replicones de ARN que codifican proteínas S del SARS CoV-2 prefusión recombinantes estabilizadas. También se describen composiciones farmacéuticas y usos de los replicones de ARN.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063023150P | 2020-05-11 | 2020-05-11 | |
PCT/IB2021/054022 WO2021229448A1 (en) | 2020-05-11 | 2021-05-11 | Rna replicon encoding a stabilized corona virus spike protein |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014167A true MX2022014167A (es) | 2023-02-14 |
Family
ID=76011974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014167A MX2022014167A (es) | 2020-05-11 | 2021-05-11 | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210347828A1 (es) |
EP (1) | EP4149537A1 (es) |
JP (1) | JP2023525785A (es) |
KR (1) | KR20230009489A (es) |
CN (1) | CN116096409A (es) |
AU (1) | AU2021271300A1 (es) |
BR (1) | BR112022022942A2 (es) |
CA (1) | CA3183498A1 (es) |
MX (1) | MX2022014167A (es) |
WO (1) | WO2021229448A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116348136A (zh) * | 2020-08-27 | 2023-06-27 | 希力德株式会社 | 新型冠状病毒重组刺突蛋白、编码该重组刺突蛋白的多核苷酸、包含多核苷酸的载体以及包含载体的用于预防或治疗冠状病毒感染的疫苗 |
WO2023098842A1 (en) * | 2021-12-03 | 2023-06-08 | Suzhou Abogen Biosciences Co., Ltd. | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN |
US11931410B1 (en) | 2022-01-27 | 2024-03-19 | Shenzhen Rhegen Biotechnology Co., Ltd. | SARS-CoV-2 mRNA vaccine and preparation method and use thereof |
CA3207885A1 (en) * | 2022-02-07 | 2023-08-07 | Seqirus Inc. | Self-replicating rna and uses thereof |
WO2023220693A1 (en) * | 2022-05-12 | 2023-11-16 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
WO2012006369A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
WO2017037196A1 (en) | 2015-09-02 | 2017-03-09 | Janssen Vaccines & Prevention B.V. | Stabilized viral class i fusion proteins |
EP3526332B1 (en) | 2016-10-17 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
MX2021004032A (es) | 2018-10-08 | 2021-07-06 | Janssen Pharmaceuticals Inc | Replicones basados en alfavirus para la administracion de bioterapeuticos. |
-
2021
- 2021-05-11 MX MX2022014167A patent/MX2022014167A/es unknown
- 2021-05-11 AU AU2021271300A patent/AU2021271300A1/en active Pending
- 2021-05-11 WO PCT/IB2021/054022 patent/WO2021229448A1/en unknown
- 2021-05-11 EP EP21726719.4A patent/EP4149537A1/en active Pending
- 2021-05-11 BR BR112022022942A patent/BR112022022942A2/pt not_active Application Discontinuation
- 2021-05-11 US US17/317,322 patent/US20210347828A1/en active Pending
- 2021-05-11 CN CN202180034708.7A patent/CN116096409A/zh active Pending
- 2021-05-11 CA CA3183498A patent/CA3183498A1/en active Pending
- 2021-05-11 JP JP2022568501A patent/JP2023525785A/ja active Pending
- 2021-05-11 KR KR1020227043408A patent/KR20230009489A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CN116096409A (zh) | 2023-05-09 |
KR20230009489A (ko) | 2023-01-17 |
EP4149537A1 (en) | 2023-03-22 |
US20210347828A1 (en) | 2021-11-11 |
WO2021229448A1 (en) | 2021-11-18 |
JP2023525785A (ja) | 2023-06-19 |
BR112022022942A2 (pt) | 2022-12-13 |
AU2021271300A1 (en) | 2023-02-02 |
CA3183498A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014167A (es) | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. | |
ATE549028T1 (de) | Stabile analoga von glp-1 | |
MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
ATE539089T1 (de) | Cyclische rezeptor-assoziierte-proteine (rap)- peptide | |
CY1117162T1 (el) | Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης | |
MX2022014162A (es) | Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas. | |
MX2018003702A (es) | Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden. | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
DE60329089D1 (de) | Zytoplasmatische transduktionspeptide und deren verwendungen | |
EA200602257A1 (ru) | Стабилизированные жидкие препаративные формы интерферона | |
MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
ATE551048T1 (de) | Proteinhydrolysate enthaltende kosmetische zusammensetzungen | |
HRP20050024A2 (en) | Pegylated t20 polypeptide | |
WO2020061229A3 (en) | Arc-based capsids and uses thereof | |
MX2022014161A (es) | Vacunas contra sars-cov-2. | |
BRPI0516576B8 (pt) | vetores quiméricos | |
DE602004028246D1 (de) | Analoga von peptiden der relaxin-superfamilie | |
PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
BR112022009217A2 (pt) | Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos | |
MX2022002766A (es) | Vacunas contra el virus de la gripe y usos de las mismas. | |
MX2018000023A (es) | Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina. | |
WO2018115509A3 (en) | New flavivirus vaccine |